Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 1.00 |
| ▸ | TK1 | P04183 | 4/20 | 0.56 |
| ▸ | TK2 | O00142 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22992433 | 1.00 | RNASE1 (1.00) | RNASE1TK1TK2POLBALB | |
| SCHEMBL3279568 | 1.00 | RNASE1 (1.00) | RNASE1TK1TK2POLBALB | |
| SCHEMBL7875887 | 1.00 | RNASE1 (1.00) | RNASE1TK1TK2POLBALB | |
| SCHEMBL7875892 | 1.00 | RNASE1 (1.00) | RNASE1TK1TK2POLBALB | |
| Barbituric Acid SCHEMBL9710100 | 0.93 | RNASE1 (0.86) | RNASE1TK1TK2POLB | |
| SCHEMBL9326675 | 0.90 | RNASE1 (0.82) | RNASE1TK1TK2 | |
| SCHEMBL13273339 | 0.90 | RNASE1 (0.82) | RNASE1TK1TK2 | |
| SCHEMBL21886791 | 0.90 | RNASE1 (0.82) | RNASE1TK1TK2 | |
| SCHEMBL22992340 | 0.90 | RNASE1 (0.82) | RNASE1TK1TK2 | |
| SCHEMBL30976654 | 0.90 | RNASE1 (0.82) | RNASE1TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| US-20110104754-A1 | CELL CULTURE MEDIUM | GENETIX LIMITED | 2011-05-05 | — | — | US | disclosed |
| EP-1818392-B1 | Cell culture medium | GENETIX LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| US-20100087634-A1 | Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides | BERRY & ASSOCIATES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20070212778-A1 | Cell culture medium | GENETIX LIMITED | 2007-09-13 | — | — | US | disclosed |
| EP-1831238-A2 | FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | Berry & Associates , Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1818392-A1 | Cell culture medium | Genetix Limited (GB) | 2007-08-15 | — | — | EP | disclosed |
| EP-0586570-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5264566-A | Method for in vitro oligonucleotide synthesis using H-phosphonates | GENENTECH, INC. (US) | 1993-11-23 | — | — | US | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| WO-1992020822-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| US-5166330-A | Phosphonation, amination and reaction with nucleosides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-24 | — | — | US | disclosed |
| EP-0406309-A4 | OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES | — | 1992-08-19 | — | — | EP | disclosed |
| EP-0406309-A1 | OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES | THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1991-01-09 | — | — | EP | disclosed |
| US-4959463-A | Intermediates | GENENTECH, INC. (US) | 1990-09-25 | — | — | US | disclosed |
| WO-1989009221-A1 | OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1989-10-05 | — | — | WO | disclosed |
| EP-0219342-A2 | Method and reagents for in vitro oligonucleotide synthesis | GENENTECH, INC. (US) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | RNASE1 1587/4885TK1 22/4885TK2 68/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | RNASE1 1587/4885TK1 22/4885TK2 68/4885 |
| US-20100087634-A1 | Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides | DCLRE1B, POLM, FBL | RNASE1 171/4885TK1 23/4885TK2 460/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | RNASE1 1587/4885TK1 22/4885TK2 68/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | RNASE1 1587/4885TK1 22/4885TK2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.